Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Accumulated Expenses (2020 - 2026)

Mereo BioPharma has reported Accumulated Expenses over the past 7 years, most recently at $2.0 million for Q1 2026.

  • Quarterly Accumulated Expenses fell 30.22% to $2.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Mar 2026, down 30.22% year-over-year, with the annual reading at $2.0 million for FY2025, 50.23% down from the prior year.
  • Accumulated Expenses was $2.0 million for Q1 2026 at Mereo BioPharma, up from $2.0 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $6.4 million in Q2 2022 and troughed at $2.0 million in Q4 2025.
  • The 5-year median for Accumulated Expenses is $3.9 million (2024), against an average of $3.9 million.
  • The largest YoY upside for Accumulated Expenses was 35.47% in 2025 against a maximum downside of 50.23% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $5.3 million in 2022, then increased by 3.78% to $5.5 million in 2023, then decreased by 25.54% to $4.1 million in 2024, then plummeted by 50.23% to $2.0 million in 2025, then increased by 0.99% to $2.0 million in 2026.
  • Per Business Quant, the three most recent readings for MREO's Accumulated Expenses are $2.0 million (Q1 2026), $2.0 million (Q4 2025), and $4.1 million (Q3 2025).